Financial Report: Bristol-Myers Squibb 3Q11

Bristol-Myers Squibb 3Q11
 

3Q Revenues: $5.3 billion (+11%)
 

3Q Earnings: $969 million (+2%) 
 

YTD Revenues: $15.8 billion (+10%)
 

YTD Earnings: $2.9 billion (+9%)
 

Comments: U.S. sales increased 11% in the quarter to $3.5 billion. International sales increased 12%, or 4% excluding foreign exchange, to $1.9 billion. Plavix sales were up 8% in the quarter to $1.8 billion. Baraclude sales were $311 million, up 36%. Orencia sales were $233 million, up 27%. Sprycel sales jumped 47% to $211 million. Avapro/Avalide sales were down 29% to $216 million. R&D expenses increased 18% to $973 million in the quarter.